Company intelligence / Profile preview

Vakzine Projekt Management

Hannover, Lower Saxony, Germanysls-eu.com ↗

Ownership: Private
Employees: ~6
Development stage: Phase 3

Overview

Vakzine Projekt Management has successfully advanced several biopharmaceutical candidates from preclinical through clinical phases I–III and marketing authorization. Notable programs include a second-generation interferon beta for multiple sclerosis in preclinical development, a live recombinant tuberculosis vaccine in Phase 2 trials in South Africa, and a preventive human cytomegalovirus vaccine in preclinical development

Therapeutic areas: OncologyNeurologyInfectious Diseases
Modalities: Small moleculeRecombinant proteinGene-modified live vaccineAdvanced therapy medicinal product (ATMP)Vaccine
Industry: Biotech

Drug pipeline

1 asset

VPM4001

Unknown

Partnerships

Academic research institutionsindustry partners sought for co-development and investment

Beyond the preview

Go deeper on Vakzine Projekt Management.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vakzine Projekt Management.

Explore the full profile